Mural Oncology PLC SEC Filings

Mural Oncology plc (MURA) reported an insider transaction on a Form 4. On 11/10/2025, the reporting person sold 5,036 ordinary shares at $2.08 (code S) to satisfy tax withholding tied to the vesting of restricted stock units under a Rule 10b5-1 plan.

After the sale, the insider beneficially owned 84,727 shares, which includes 71,509 unvested RSUs. The filer is listed as an officer (Chief Medical Officer).

Mural Oncology plc (MURA) filed its Q3 2025 10‑Q, reporting a pending all‑cash acquisition by XOMA Royalty Corporation. Shareholders approved the deal, which provides a base cash price of $2.035 per share and up to an additional $0.205 per share, subject to closing conditions.

The company ended the quarter with cash and cash equivalents of $58.9 million and reported a Q3 net loss of $3.7 million. Year‑to‑date, net loss was $84.8 million, with cash used in operations of $86.6 million. A change in estimate after closing out ARTISTRY‑6 reduced R&D expense by about $4.8 million in Q3.

Mural previously discontinued all clinical development of nemvaleukin following unfavorable trial results, ceased preclinical programs, and completed a ~90% workforce reduction, incurring $17.5 million in restructuring and impairment during the nine‑month period. The company disclosed substantial doubt about its ability to continue as a going concern pending completion of the XOMA transaction. As of November 3, 2025, 17,344,486 ordinary shares were outstanding.

Mural Oncology reported that shareholders approved the company’s acquisition by XOMA Royalty via a court‑sanctioned Irish scheme of arrangement. At the Scheme Meeting, Proposal 1 passed with 10,103,706 for, 81,149 against and 52,031 abstaining, satisfying the required majority in number and at least 75% of the value of shares voted.

At the Extraordinary General Meeting, shareholders approved the Scheme (Proposal 1) with 10,607,228 for, 89,435 against and 13,056 abstaining, and approved an articles amendment (Proposal 2) with 10,647,967 for, 48,436 against and 13,316 abstaining, ensuring shares issued after the record time are captured by the Scheme or acquired for the scheme consideration. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions and the sanction of the Scheme by the High Court of Ireland.

Mural Oncology plc filed a DEFM14A proxy describing a proposed acquisition by XOMA Royalty (via Sub XRA 5 Corp.) structured as a scheme of arrangement. The Transaction Agreement sets a Base Price of $2.035 per Mural Share plus an Additional Price per Share up to $0.205. The Scheme Meeting is scheduled for October 24, 2025 with a Voting Record Time of 10:00 p.m. (Irish) on September 18, 2025. The filing discloses that Mural discontinued clinical development of nemvaleukin after ARTISTRY-7 failed to meet its primary endpoint and, following ARTISTRY-6 review, announced on April 15, 2025 the cessation of all nemvaleukin development and exploration of strategic alternatives. The Board approved a workforce reduction of approximately 104 positions (~90%), and on June 3, 2025 Mural ceased remaining preclinical program activities. The proxy also details voting procedures, indemnity exposure under a Tax Matters Agreement related to the Separation from Alkermes, executive severance estimates, and mechanics of the Scheme and potential reimbursement and termination provisions.

Trium Capital LLP reports beneficial ownership of 1,760,097 ordinary shares of Mural Oncology plc, representing 10.16% of the outstanding class. The filing states Trium has sole voting and sole dispositive power over these shares, and that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The document identifies the security as ordinary shares with nominal value $0.01 and provides the issuer's principal office in Dublin, Ireland.

Trium Capital LLP filed an SEC Form 3 disclosing initial beneficial ownership in Mural Oncology plc (MURA US). The filing reports 1,760,097 shares of MURA held directly. The event date listed is 08/22/2025 and the form is signed by Fredrik Ostlund on 09/02/2025. The filing identifies the reporting person as a Director.

Mural Oncology plc disclosed a transaction agreement dated August 20, 2025, among Mural Oncology plc, XOMA Royalty Corporation and XRA 5 Corp. The filing describes mutual termination rights: the Company may terminate if the bidder breaches material covenants or if the Board approves a Superior Proposal before shareholder approval; the bidder may terminate for the Companys material breach, a Board change in recommendation, or if the Company solicits a Superior Proposal and does not cure within 15 days.

The filing also includes customary forward-looking disclaimers and lists related exhibits and communications, including a Rule 2.7 announcement, Rule 2.10 letters to shareholders and employees, a directors irrevocable undertaking, and the transaction agreement as exhibits. The disclosures focus on deal mechanics and termination conditions rather than financials.

Mural Oncology plc received a joint Schedule 13G/A from Armistice Capital, LLC and Steven Boyd reporting that the reporting persons do not beneficially own any ordinary shares of the issuer. The filing states zero shares owned and 0% of the class based on 17,324,359 shares outstanding as reported by the issuer.

The filing explains that Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and that Armistice Capital exercises voting and investment power over the Master Fund's securities. The Master Fund disclaims beneficial ownership due to its inability to vote or dispose of the securities under the investment management agreement. The Master Fund retains the right to receive dividends or sale proceeds.

Mural Oncology plc received an amended Schedule 13G filing from Solas Capital Management, LLC and Frederick Tucker Golden reporting that neither the adviser nor Mr. Golden beneficially own any ordinary shares of the company. The filing lists the issuer's Dublin address and the security CUSIP G63365103. Both reporting parties state 0 shares owned and 0.0% of the class, and clarify the adviser relationship to private funds while noting the funds disclaim beneficial ownership. Signatures by Frederick Tucker Golden certify the accuracy of the statement.